''The last year was a milestone for us'' says Arnab Basu, chief executive of medical and nuclear screening group Kromek PLC (LON:KMK).

''We won US$80mln of new contracts to make the total US$145mln over the past three years.''

''As these contracts are multi-year in nature we have visibility on 80% of revenues this year as well.''

Sales rose 23% in the year to April, underlying profits rose four-fold and losses halved and Basu expects further improvement in the current twelve months.

New standards are coming in for airport screening security while health authorities are realising diagnostics is a crucial way to improve the effectiveness of treatment.

Meanwhile, China and India are markets that are just opening up.